Description
| DSIP 5MG | |
|---|---|
| SKU | CP_DSIP_5MG_3ML_VIAL |
| CATEGORY | Research Compounds |
| CAS | 62568-57-4 |
| VIAL SIZE | 3 mL |
| FORM | LYOPHILIZED POWDER |
| MOLECULAR WEIGHT | 848.82 g/mol |
| SEQUENCE | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| MOLECULAR FORMULA | C35H48N10O15 |
| ITEM ID | 11681 |
Tukhovskaya et al. (2021) investigated DSIP in a rat model of focal stroke induced by intraluminal middle cerebral artery occlusion (MCAO). DSIP was administered over an 8-day course beginning prior to occlusion and continuing through reperfusion. A battery of behavioral assessments – including rotarod testing for motor coordination and balance – was performed at multiple time points over 21 days. Brain infarction volume was measured from serial cryosections at study termination. The authors reported that DSIP-treated animals showed significantly accelerated recovery of motor performance on the rotarod test compared to vehicle-treated controls, although the difference in brain infarction volume did not reach statistical significance [1].
